Total
0
Shares
MGC Pharma (ASX:MXC) - Co Founder and Managing Director, Roby Zomer - The Market Herald
Co Founder and Managing Director, Roby Zomer
Source: FinFeed
  • MGC Pharmaceuticals (MXC) has issued almost 3300 prescriptions of its standardised cannabinoid medicines in Australia, U.K., Ireland, and Brazil
  • This represents a 64 per cent increase in prescriptions since January
  • As a result of this increase, MGC Pharma will begin rolling out its expanded Mercury MGC Pharma product line to include six extra products with higher percentages of CBD and THC
  • MGC Pharma is up a steady 4.35 per cent and shares are trading for 2.4 cents each

MGC Pharmaceuticals (MXC) has issued 3295 prescriptions of its standardised cannabinoid medicines in Australia, U.K., Ireland, and Brazil.

This represents a 64 per cent increase in prescriptions since January.

The majority of these prescriptions were CannEpil, MXP100, and MP100, and an average of 35 per cent of repeat patients received two or more prescriptions.

Source: MGC Pharmaceuticals

Further, since its first patient received medication of CogniCann in mid-January, 50 prescriptions have been issued to 23 patients.

Both of these achievements represent a significant milestone for MGC Pharma given that higher than expected sales have been received despite COVID-19.

As a result of these increases, MGC Pharma will begin rolling out its expanded Mercury MGC Pharma product line to include six extra products with higher percentages of CBD (cannabidiol) and THC (tetrahydrocannabinol) to exiting markets.

The company is confident that this expansion will be well received given the strong pipeline for its exisiting products.

Based off recent evaluations, MGC Pharma has ended its product distribution exclusivity agreement with GrowBiotech to allow it to focus on new sales and distribution partnerships in the U.K.

"The company is extremely pleased to have achieved the strong growth in both prescription and patient numbers in what has been a challenging operating environment due to the outbreak of COVID-19," Co-Founder and Managing Director Roby Zomer commented.

"The company is responding to the current strong order pipeline and we look forward to further sales growth opportunities with the expansion of the Mercury MGC Pharma line of products," he added.

A review of scheduling low-dose CBD, which will be considered at the Australian Therapeutic Goods Administration (TGA) Joint Advisory Committee in June, may result in some CBD medicines being reclassified to a lower classification.

This will allow low-dose CBD products to be purchased at pharmacies without a prescription.

MGC Pharma is up a steady 4.35 per cent and shares are trading for 2.4 cents each at 3:16 pm AEST.


Subscribe


MXC by the numbers
More From The Market Herald
LBT Innovations (ASX:LBT) - CEO, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) signs agreement with leading EU medical distributor

Meditech company LBT Innovations (LBT) has signed a marketing agent agreement with Beckman Coulter for the marketing of the APAS Independence in Europe.
Fiji Kava (ASX:FIJ) - CEO & Founder, Zane Yoshida - The Market Herald

" Fiji Kava (ASX:FIJ) partners with PHAMA Plus Program

Fiji Kava (FIJ) has partnered with the Pacific Horticultural and Agricultural Market Access (PHAMA) Plus Program to strengthen kava export opportunities.
eSense Lab (ASX:ESE) - CEO, Itzik Mizrahi - The Market Herald

" eSense-Lab (ASX:ESE) lands $10M sales deal with States-based Blue Science

Terpene-based sanitiser developer eSense-Lab (ESE) has locked in a potential $10 million sales contract with United States-based Blue Science Solutions.
Allegra Orthopaedics (ASX:AMT) - CEO, Jenny Swain - The Market Herald

" Allegra Orthpaedics (ASX:AMT) soars 500pc after buying synthetic bone patents

Medical company Allegra Orthopaedics (AMT) topped the winner’s chart by quite some distance today after buying the patents for a synthetic bone substitute